{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Llewellyn-Bennett R"],"funding":["National Centre for the Replacement, Refinement and Reduction of Animals in Research","Medical Research Council","Alzheimers Research UK","National Institute for Health Research (NIHR)","Alzheimer's Society","Royal College of Surgeons of England"],"pagination":["298"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5975470"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(1)"],"pubmed_abstract":["<h4>Background</h4>Randomised controlled clinical trials typically have a relatively brief in-trial follow-up period which can underestimate safety signals and fail to detect long-term hazards, which may take years to appear. Extended follow-up after the scheduled closure of the trial allows detection of both persistent or enhanced beneficial effects following cessation of study treatment (i.e. a legacy effect) and the emergence of possible adverse effects (e.g. development of cancer).<h4>Methods</h4>A systematic review was conducted following PRISMA guidelines to qualitatively compare post-trial follow-up methods used in large randomised controlled trials. Five bibliographic databases, including Medline and the Cochrane Library, and one trial registry were searched. All large randomised c"],"journal":["Trials"],"pubmed_title":["Post-trial follow-up methodology in large randomised controlled trials: a systematic review."],"pmcid":["PMC5975470"],"funding_grant_id":["MC_U137686861","MR/L023784/2","CL-2015-16-001","HDR-4002","Research Fellowship","ART-PPG2005A-2","151","G0800701/1","ARUK-PPG2014A-8"],"pubmed_authors":["Hainsworth AH","Bowman L","Edwards D","Roberts N","Llewellyn-Bennett R","Bulbulia R"],"additional_accession":[]},"is_claimable":false,"name":"Post-trial follow-up methodology in large randomised controlled trials: a systematic review.","description":"<h4>Background</h4>Randomised controlled clinical trials typically have a relatively brief in-trial follow-up period which can underestimate safety signals and fail to detect long-term hazards, which may take years to appear. Extended follow-up after the scheduled closure of the trial allows detection of both persistent or enhanced beneficial effects following cessation of study treatment (i.e. a legacy effect) and the emergence of possible adverse effects (e.g. development of cancer).<h4>Methods</h4>A systematic review was conducted following PRISMA guidelines to qualitatively compare post-trial follow-up methods used in large randomised controlled trials. Five bibliographic databases, including Medline and the Cochrane Library, and one trial registry were searched. All large randomised c","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 May","modification":"2025-04-18T17:31:43.136Z","creation":"2019-03-26T23:39:39Z"},"accession":"S-EPMC5975470","cross_references":{"pubmed":["29843774"],"doi":["10.1186/s13063-018-2653-0"]}}